Clinical trial
Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
NCT00204529 · University Hospital Tuebingen, Other · Completed
Key facts
| NCT number | NCT00204529 |
|---|---|
| Title | Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB |
| Official title | Randomized, Multicenter, Open Label Study to Compare the Efficacy and Tolerability of Pegylated Interferon-alpha-2 (PEG-IFN) to 'Low-dose' Interferon-alpha-2a in Patients With Malignant Melanoma in Stages IIA (T3a) - IIIB (AJCC 2002) |
| Lead sponsor | University Hospital Tuebingen, Other |
| Collaborators | Dermatologic Cooperative Oncology Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | pegylated interferon-alpha-2a, interferon-alpha-2a |
| Enrollment | 901 |
| Start date | Oct 1, 2004 |
| Primary completion | May 1, 2013 |
| Completion | Dec 1, 2016 |
| First posted | Sep 20, 2005 |
| Last update posted | May 3, 2017 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: